Joenja (leniolisib) is a medicine whose European Public Assessment Report (EPAR) status is "Opinion". An EPAR is a document that provides public information about the evaluation of a medicine by the European Medicines Agency (EMA). The "Opinion" status indicates that the EMA has issued an opinion on Joenja (leniolisib). Further information about this opinion and the entire evaluation process is available in the EPAR report itself. This report is intended for the public and healthcare professionals looking for detailed information about the medicine. The goal of EPAR is to ensure the transparency of the drug approval process in the European Union.